As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign
Walkerssk / Pixabay

As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

According to a story from express.co.uk, Elle Morris was only 11 years old when she died from a severe lung infection. Elle was born with cystic fibrosis, a serious genetic…

Continue Reading As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma

According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc recently announced encouraging results from an interim safety review of the company's Phase 2a clinical trial. This…

Continue Reading Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma
New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome
jarmoluk / Pixabay

New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome

According to a publication from Karolinska Institutet, a medical research university near Stockholm, Sweden, new research led by the University suggests that regulatory T cells have an especially important role…

Continue Reading New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome

Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance

In about five years India’s population will exceed that of China which is currently ranked number one according to population. Contrast these numbers with the fact that only ten percent…

Continue Reading Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance
Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy
Pexels / Pixabay

Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

According to a story from globenewswire.com, the biotechnology company Biogen recently released data from an open label study that was testing the company's spinal muscular atrophy drug nusinersen (marketed as…

Continue Reading Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

Ash Clinical News recently interviewed Dr. Bruce Leff of Johns Hopkins in connection with “hospital-at-home”, one of the major changes occurring in hospital care. Dr. Leff and his team at…

Continue Reading In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug
Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
https://pixabay.com/en/technology-robot-human-hand-2025795/

Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run

According to an article from CW associate WBCB, Dutch startup Nori Health has started open enrollment in the six-week test of its eponymous experimental chatbot, Nori. Nori aims to help…

Continue Reading Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run